Polpharma, one of Poland’s largest pharmaceutical companies, is expanding its operations internationally with the acquisition of Romanian firm Biofarm. This move follows Polpharma’s earlier success in Kazakhstan, where it took over the country’s largest pharmaceutical manufacturer 16 years ago.
The acquisition of Biofarm has been finalized, as reported by IMAP, which advised Polpharma throughout the transaction. Prior to this offer, Polpharma secured irrevocable commitments to sell shares from Biofarm’s two largest shareholders, Longshield Investment Group and Lion Capital, who together control approximately 88.43% of Biofarm’s equity.
In May, Biofarm announced it received notifications from Longshield and Lion Capital, who hold a combined 88.4257% share of the company, along with Polpharma regarding a strategic agreement established on May 6, 2026. This agreement includes a public offer by Polpharma to acquire all outstanding shares at a price of 1.379 RON per share, with Longshield and Lion Capital committed to offering all of their Biofarm shares through this public offer.
Biofarm has a total capital of 985 million 375 thousand 350 shares, meaning the acquisition value is approximately 1.11 billion PLN. The company ranks among the top 10 pharmaceutical manufacturers in Romania by sales volume and has been listed on the Bucharest Stock Exchange since 2005. Biofarm operates two drug manufacturing facilities in Bucharest and has a unit dedicated to product testing and development. Its portfolio includes over 100 products covering key therapeutic areas in Consumer Healthcare, such as digestive and metabolic systems, respiratory and laryngological systems, cardiovascular systems, neurological systems, and vitamins.
Employing nearly 6,000 people, Polpharma is the largest pharmaceutical producer in Poland. In 2025, the group reported an 8.8% increase in revenues, totaling 5.3 billion PLN, while net profit grew by 0.7% to 1.1 billion PLN. Last year, the company distributed 1.85 billion PLN in dividends to its shareholders, although investments fell by 12% to 384 million PLN.
